Dalila Sellami

Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib

Andrew X. Zhu, Masatoshi Kudo, Eric Assénat et al. · JAMA · 2014 · 569 citations · Full text

Medicine, Oncology, Pharmacology +17

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, Carlos H. Barrios, Tae Min Kim et al. · Journal of Clinical Oncology · 2014 · 431 citations · Full text

Medicine, Oncology, Pharmacology +15

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

Michael R. Migden, Alexander Guminski, Ralf Gutzmer et al. · The Lancet Oncology · 2015 · 429 citations

Medicine, Dermatology, Oncology +7

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Angelo Di Leo, Stephen Johnston, Keun Seok Lee et al. · The Lancet Oncology · 2017 · 381 citations

Medicine, Oncology, Pharmacology +16

HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

Helena A. Yu, Yasushi Goto, Hidetoshi Hayashi et al. · Journal of Clinical Oncology · 2023 · 225 citations · Full text

Medicine, Oncology, Pharmacology +14